BioCorp and Roche Diabetes Care France announced the launch of the Mallya smart insulin pen device in France. Developed by BioCorp, Mallya is an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen. It enables reliable monitoring for doses selected for injection and it offers […]
Patient Monitoring
Pear Therapeutics inks multiple agreements to expand digital therapeutic platform
Pear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform. Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release. The agreements have been struck with technology companies including Empatica, […]
Welldoc, Dexcom expand diabetes management tech partnership
Welldoc announced today that it will offer its BlueStar digital health solution with Dexcom’s G6 CGM system as a single platform. Columbia, Md.-based Welldoc’s FDA-cleared BlueStar system offers guidance to individuals through the self-management of diabetes, while Dexcom’s G6 continuous glucose monitoring (CGM) system measures glucose levels just beneath the skin’s surface and wirelessly transmits […]
Prescryptive to offer benefit coverage for Pear Therapeutics opioid use disorder treatments
Pear Therapeutics announced today that Prescryptive Health will offer and administer benefit coverage for its digital therapeutics. Boston-based Pear Therapeutics’ reSET and reSET-O, two FDA-cleared prescription digital therapeutics (PDTs) for treating substance and opioid use disorder, have been added to Prescryptive’s formularies and are being administered as standard pharmacy benefits for its members, according to […]
Glytec launches new insulin management system
Glytec announced today that it introduced the latest version of its eGlycemic Management System (eGMS) for managing insulin. Waltham, Mass.-based Glytec’s eGMS is centered around the FDA-cleared Glucommander algorithm, which leverages real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs, leading to a personalized treatment regime […]
BrightInsight raises $101M for its pre-built digital health platform
BrightInsight announced today that it’s raised $101 million in a Series C round led by VC firm General Catalyst. The money will go toward more hiring and further accelerating the work BrightInsight is conducting with customers to support their digital health product launches. The San Jose, Calif.–based company offers a turnkey digital health platform for […]
BioCorp, Diabeloop partner on diabetes management tech development
BioCorp and Diabeloop announced today that they are entering a cooperation agreement to develop new personalized diabetes treatments. Diabeloop develops automated insulin delivery (AID) systems, including a self-learning algorithm hosted in a handset and connected to a continuous glucose monitoring (CGM) system and an insulin pump. The platform analyzes glucose data, calculates the right dose […]
Insulet touts results from Omnipod 5 study, expects launch this year
Insulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system. Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release. Acton, Mass.-based Insulet said the device, which has FDA breakthrough device […]
Bigfoot Biomedical raises $57M to support its diabetes management tech
Bigfoot Biomedical announced today that it secured $57 million in financing as it works toward commercializing its diabetes management program. Madryn Asset Management provided the financing for Bigfoot, which is developing the Bigfoot Unity diabetes management program designed to simplify and connect aspects of insulin management to enable personalized, proactive and remote patient care, according […]
Senseonics sinks on mixed bag Q4, massive bottom-line slide
Senseonics (NYSE:SENS) shares took a hit today on fourth-quarter losses that missed the consensus earnings forecast. SENS shares were hit hard at market close yesterday after financial results were released, dipping -15.7% to $2.69 per share. In pre-market trading this morning, they are down -7.8% at $2.48 per share. The Germantown, Md.-based implantable continuous glucose […]